Verastem Advances KRAS G12D Inhibitor into Phase 2 Trial for Pancreatic Cancer
Event summary
- Verastem dosed the first patient in the TARGET-D 201 Phase 2 trial of VS-7375 for KRAS G12D-mutated metastatic pancreatic cancer.
- The trial evaluates VS-7375 as monotherapy and in combination with cetuximab in second-line and first-line settings.
- FDA granted Fast Track Designation for VS-7375 in pancreatic and non-small cell lung cancers.
- Three registration-directed Phase 2 trials are now underway across pancreatic, lung, and colorectal cancers.
The big picture
Verastem's advancement of VS-7375 into Phase 2 trials underscores the growing focus on precision oncology for KRAS G12D mutations, which are prevalent in aggressive cancers like pancreatic and lung. The FDA's Fast Track Designation highlights the unmet need in these indications, while Verastem's multi-tumor strategy could broaden the drug's market potential if clinical success is achieved. The biotech is now racing to differentiate VS-7375 in a field with increasing competition from other KRAS inhibitors.
What we're watching
- Clinical Efficacy
- Whether VS-7375 demonstrates superior efficacy in KRAS G12D-mutated pancreatic cancer compared to existing treatments.
- Regulatory Pathway
- The pace at which Verastem can secure additional regulatory designations for VS-7375 across multiple tumor types.
- Commercial Strategy
- How Verastem positions VS-7375 in a competitive landscape with emerging KRAS-targeted therapies.